Insider Selling: CeriBell (NASDAQ:CBLL) CFO Sells $16,300.00 in Stock

CeriBell, Inc. (NASDAQ:CBLL) CFO Scott Blumberg sold 652 shares of the business’s stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $25.00, for a total transaction of $16,300.00. Following the completion of the sale, the chief financial officer directly owned 146,600 shares in the company, valued at approximately $3,665,000. This trade represents a 0.44% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Scott Blumberg also recently made the following trade(s):

• On Friday, August 21st, Scott Blumberg sold 1,521 shares of CeriBell stock. The stock was sold at an average price of $24.02, for a total transaction of $36,534.42.
• On Wednesday, August 19th, Scott Blumberg sold 33,512 shares of CeriBell stock. The shares were sold at an average price of $25.03, for a total transaction of $838,805.36.
• On Tuesday, August 18th, Scott Blumberg sold 990 shares of CeriBell stock. The stock was sold at an average price of $25.00, for a total value of $24,750.00.

CeriBell Price Performance

CeriBell stock opened at $24.72 on Monday. The firm has a market capitalization of $948.75 million, a P/E ratio of -14.05 and a beta of 0.95. CeriBell, Inc. has a one year low of $10.85 and a one year high of $25.33. The company has a debt-to-equity ratio of 0.16, a current ratio of 9.18 and a quick ratio of 8.79. The business has a fifty day moving average price of $20.67 and a 200-day moving average price of $19.49.

CeriBell (NASDAQ:CBLL) last released its quarterly earnings data on Monday, August 10th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.04). CeriBell had a negative net margin of 64.73% and a negative return on equity of 44.85%. The company had revenue of $28.10 million for the quarter, compared to the consensus estimate of $27.28 million. As a group, equities research analysts forecast that CeriBell, Inc. will post -1.96 EPS for the current year.

Institutional Investors Weigh In On CeriBell

Hedge funds have recently bought and sold shares of the stock. BlackRock Inc. purchased a new stake in shares of CeriBell during the 2nd quarter valued at $37,657,000. Bank of New York Mellon Corp grew its position in CeriBell by 1,945.9% in the fourth quarter. Bank of New York Mellon Corp now owns 1,221,927 shares of the company’s stock worth $26,797,000 after acquiring an additional 1,162,200 shares in the last quarter. KCM Capital Inc bought a new position in CeriBell in the fourth quarter valued at $21,930,000. TimesSquare Capital Management LLC purchased a new stake in CeriBell during the second quarter valued at about $15,182,000. Finally, Royce & Associates LP purchased a new stake in CeriBell during the fourth quarter valued at about $11,695,000.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on CBLL shares. Barclays upgraded shares of CeriBell to a “neutral” rating in a research report on Tuesday, August 18th. Raymond James Financial reissued a “strong-buy” rating and issued a $29.00 price target on shares of CeriBell in a report on Thursday. Weiss Ratings lowered shares of CeriBell from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, August 28th. BTIG Research upped their price target on shares of CeriBell from $28.00 to $30.00 and gave the stock a “buy” rating in a report on Tuesday, August 18th. Finally, Canaccord Genuity Group lifted their price objective on CeriBell from $25.00 to $26.00 and gave the company a “buy” rating in a research note on Tuesday, August 11th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, CeriBell currently has a consensus rating of “Moderate Buy” and an average price target of $24.40.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.